Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neurooncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neurooncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
复制标题
DOI：
10.1093/neuonc/noaa277
复制
发表时间：
2021-03-01
期刊：
影响因子：
15.9
通讯作者：
Okada, Hideho
中科院分区：
文献类型：
--
作者：
Chuntova, Pavlina;Chow, Frances;Okada, Hideho
自2015年以来，癌症免疫治疗取得了显着进展，美国食品药品监督管理局（FDA）批准了50多个单独的一线或二线适应症。这些包括免疫检查点阻断抗体、嵌合抗原受体转导的T细胞和双特异性T细胞接合抗体。虽然多种癌症类型现在受益于这些免疫疗法，但迄今为止值得注意的例外包括脑肿瘤，如胶质母细胞瘤。因此，更好地了解恶性胶质瘤对免疫疗法的抵抗的独特机制挑战以及深入了解未来策略的发展似乎至关重要。在2019年度神经肿瘤学会科学会议期间举行了免疫肿瘤学智库会议。神经肿瘤学、神经外科学、神经影像学、内科肿瘤学和癌症免疫学领域的讨论者参加了会议。会议重点关注肿瘤微环境，骨髓细胞，T细胞功能障碍，细胞工程和翻译方面等主题，这些方面是原发性脑肿瘤固有的关键和独特的挑战。在这篇综述中，我们总结了会议的讨论和关键信息，这可能会成为以合作方式推进免疫神经肿瘤学领域的基础。
Cancer immunotherapy has made remarkable advances with over 50 separate Food and Drug Administration (FDA) approvals as first- or second-line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T cells, and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights into the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells, T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.